Menu
Recruiting NCT03002272

Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study

Observational Aortic Valve Replacement

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: TAVR, SAVR.
Who it may be relevant to
Registry conditions: Aortic Valve Replacement. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

In this observational study, the investigators will enroll subjects who underwent TAVR or SAVR more than 3 years ago. Clinical and procedural data from the implant/surgery will be collected, alongside clinical and echocardiographic data from subsequent follow-up visits.

Detailed description

There is limited available information on long term TAVR valve function. In this observational study, the investigators will enroll subjects who underwent TAVR or SAVR more than 3 years ago. Clinical and procedural data from the implant/surgery will be collected, alongside clinical and echocardiographic data from subsequent follow-up visits. Up-to-date echocardiography will be performed and analyzed in a Core Lab to assess valve function yearly.

Interventions

  • Device TAVR
    subjects that underwent TAVR more than 3 years ago
  • Device SAVR
    Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago

Primary outcome measures

  • Prosthetic valve dysfunction [Time frame: 7 years]
Secondary outcome measures (2)
  • Change in functional status [Time frame: discharge from hospital]
  • Increase in severity of aortic regurgitation [Time frame: upto 7 years]

Eligibility criteria

Inclusion criteria for TAVR subjects

a) TAVR performed more than 3 years ago

Exclusion criteria

  • Subjects unable to consent to participate, unless the subject has a legally authorized representative
  • Subjects unwilling to participate
  • Subject has undergone re-intervention to prosthetic aortic valve since TAVR procedure (e.g. balloon valvuloplasty, SAVR, re-do TAVR, paravalvular leak closure)
  • Echocardiographic evidence of prosthetic valve dysfunction within first 3 years post-TAVR (mean aortic gradient ≥20mmHg AND/OR moderate-severe transvalvular aortic regurgitation)

Inclusion criteria for SAVR subjects

  • SAVR performed more than 3 years ago
  • Propensity matched to an enrolled TAVR subject

Exclusion criteria for SAVR subjects e) Subjects unable to consent to participate, unless the subject has a legally authorized representative f) Subjects unwilling to participate g) Subject has undergone re-intervention to prosthetic aortic valve since TAVR procedure (e.g. balloon valvuloplasty, SAVR, re-do TAVR, paravalvular leak closure) h) Echocardiographic evidence of prosthetic valve dysfunction within first 3 years post-SAVR (mean aortic gradient ≥20mmHg AND/OR moderate-severe transvalvular aortic regurgitation)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

United States · 1 center
  • Washington Hospital Center — Washington D.C.

Identifiers

NCT: NCT03002272 · TAVR Durability

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗